TCGA-FD-A5BT-01A-11R-A26T-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 10.77529566
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.590
- ALLOGRAFT_REJECTION+0.530
- INTERFERON_ALPHA_RESPONSE+0.470
- ANGIOGENESIS+0.450
- COAGULATION+0.440
- INTERFERON_GAMMA_RESPONSE+0.440
- IL6_JAK_STAT3_SIGNALING+0.420
- INFLAMMATORY_RESPONSE+0.420
- MYOGENESIS+0.380
- PANCREAS_BETA_CELLS+0.380
Top 10 suppressed
- G2M_CHECKPOINT-0.370
- MITOTIC_SPINDLE-0.370
- PROTEIN_SECRETION-0.330
- E2F_TARGETS-0.320
- PEROXISOME-0.240
- MYC_TARGETS_V1-0.230
- ANDROGEN_RESPONSE-0.180
- HEME_METABOLISM-0.180
- MTORC1_SIGNALING-0.160
- PI3K_AKT_MTOR_SIGNALING-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-FD-A5BS-01A-21R-A26T-07 | — | — | 0.912 |
| 2 | MDT-AP-2584 | Med | Medulloblastoma | 0.905 |
| 3 | TCGA-E9-A1NC-01A-21R-A26B-07 | — | E | 0.903 |
| 4 | TCGA-DK-AA74-01A-11R-A39I-07 | — | — | 0.898 |
| 5 | SRR3147742 | — | — | 0.891 |
| 6 | TCGA-50-5044-01A-21R-1858-07 | — | cohortA1 | 0.889 |
| 7 | sclc0617_S65.txt | — | cohortMD2 | 0.877 |
| 8 | TCGA-77-8131-01A-11R-2247-07 | — | cohortSQ1 | 0.876 |
| 9 | 23849071-df2e-4421-b91d-90f66ec2c162 | — | — | 0.876 |
| 10 | TCGA-99-8028-01A-11R-2241-07 | — | cohortMD2 | 0.874 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.590 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.530 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.450 | Remibrutinib | — uncovered |
| COAGULATION | 0.440 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.420 | Idelalisib | — uncovered |
| MYOGENESIS | 0.380 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.380 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.370 | Inavolisib | — uncovered |
| COMPLEMENT | 0.360 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.250 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.240 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.220 | Inavolisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |